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Note
This statement states the official position of the Korean Soci-
ety of Obstetrics and Gynecology and the Korean Society of 
Gynecologic Oncology and is published jointly in the Obstet-
rics & Gynecologic Science and the Journal of Gynecologic 
Oncology. It has no legal and or political validity for clinical 
decisions.
Supplementary associated with this article can be found 
online at https://doi.org/10.5468/ogs.2020.63.2.107.
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Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as a 
primary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society of 
Gynecologic Oncology support the following scientific facts:
•  Compared to cytology, hrHPV screening has higher sensitivity and detects more cases of high-grade cervical 
intraepithelial neoplasia.
•  Qualified hrHPV testing can be considered as an alternative primary screening for cervical cancer to the current 
cytology method.
•  The starting age of primary hrHPV screening should not be before 25 years because of possible overtreatment in this 
age, which has a high human papillomavirus (HPV) prevalence but rarely progresses to cancer. The screening interval 
should be no sooner than every 3 years and no longer than every 5 years.
•  Before the introduction of hrHPV screening in Korea, research into comparative effectiveness of primary hrHPV 
screening for cervical cancer should be conducted to determine the appropriate HPV assay, starting age, and 
screening interval.
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